Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
To the Editor: Chemoprevention can prevent second primary cancers in patients with cancer, 1 but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the Journal that oral administration of an acyclic retinoid for 12 months significantly red...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1999-04, Vol.340 (13), p.1046-1047 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1047 |
|---|---|
| container_issue | 13 |
| container_start_page | 1046 |
| container_title | The New England journal of medicine |
| container_volume | 340 |
| creator | Saito, Akiko Muto, Yasutoshi Moriwaki, Hisataka |
| description | To the Editor:
Chemoprevention can prevent second primary cancers in patients with cancer,
1
but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the
Journal
that oral administration of an acyclic retinoid for 12 months significantly reduced the incidence of second primary cancers in patients who had received curative treatment for hepatocellular carcinomas,
2
but the effect on survival did not reach statistical significance after a median follow-up period of 38 months.
We have subsequently reexamined the patients every three months. Patients in whom a second primary hepatocellular carcinoma developed received mainly . . . |
| doi_str_mv | 10.1056/NEJM199904013401315 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69634561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69634561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-6ad021262700aea87c744200ae2703495eb06f3dfa7c057639baca26a6920f983</originalsourceid><addsrcrecordid>eNp9kU1LAzEQhoMotlZ_gSDBgxdZzddmN8dSqlX8KFrPS5rNYspuUpNdpf_elO1BRBwYZhie92WYAeAUoyuMUn79NL1_xEIIxBCm28TpHhjilNKEMcT3wRAhkicsE3QAjkJYoRiYiUMwwAjnguRiCMq515_atsZZ6Cr4qpWzJZx700i_gYuucT7A5QZKC8dqo2qj4ItujXWmhMbCuWxNVAf4Zdp3ONNr2Tql67qrpYcT6VUkG3kMDipZB32yqyPwdjNdTGbJw_Pt3WT8kCgm8jbhskQEE04yhKSWeaYyxsi2jxPKRKqXiFe0rGSmUJpxKpZSScIlFwRVIqcjcNH7rr376HRoi8aE7TrSateFggtOWcpxBM9_gSvXeRt3Kwihgoqc0AjRHlLeheB1Vaz7sxQYFdsPFH98IKrOdtbdstHlD01_8ghc9kDThMLqVfOv3Tc154xc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223939823</pqid></control><display><type>article</type><title>Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Saito, Akiko ; Muto, Yasutoshi ; Moriwaki, Hisataka</creator><creatorcontrib>Saito, Akiko ; Muto, Yasutoshi ; Moriwaki, Hisataka</creatorcontrib><description>To the Editor:
Chemoprevention can prevent second primary cancers in patients with cancer,
1
but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the
Journal
that oral administration of an acyclic retinoid for 12 months significantly reduced the incidence of second primary cancers in patients who had received curative treatment for hepatocellular carcinomas,
2
but the effect on survival did not reach statistical significance after a median follow-up period of 38 months.
We have subsequently reexamined the patients every three months. Patients in whom a second primary hepatocellular carcinoma developed received mainly . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199904013401315</identifier><identifier>PMID: 10189289</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antineoplastic Agents - therapeutic use ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Follow-Up Studies ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Neoplasms, Second Primary - prevention & control ; Survival Analysis ; Tretinoin - analogs & derivatives ; Tretinoin - therapeutic use</subject><ispartof>The New England journal of medicine, 1999-04, Vol.340 (13), p.1046-1047</ispartof><rights>Copyright © 1999 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-6ad021262700aea87c744200ae2703495eb06f3dfa7c057639baca26a6920f983</citedby><cites>FETCH-LOGICAL-c498t-6ad021262700aea87c744200ae2703495eb06f3dfa7c057639baca26a6920f983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199904013401315$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223939823?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26101,27922,27923,52380,54062,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10189289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Akiko</creatorcontrib><creatorcontrib>Muto, Yasutoshi</creatorcontrib><creatorcontrib>Moriwaki, Hisataka</creatorcontrib><title>Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Chemoprevention can prevent second primary cancers in patients with cancer,
1
but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the
Journal
that oral administration of an acyclic retinoid for 12 months significantly reduced the incidence of second primary cancers in patients who had received curative treatment for hepatocellular carcinomas,
2
but the effect on survival did not reach statistical significance after a median follow-up period of 38 months.
We have subsequently reexamined the patients every three months. Patients in whom a second primary hepatocellular carcinoma developed received mainly . . .</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Neoplasms, Second Primary - prevention & control</subject><subject>Survival Analysis</subject><subject>Tretinoin - analogs & derivatives</subject><subject>Tretinoin - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU1LAzEQhoMotlZ_gSDBgxdZzddmN8dSqlX8KFrPS5rNYspuUpNdpf_elO1BRBwYZhie92WYAeAUoyuMUn79NL1_xEIIxBCm28TpHhjilNKEMcT3wRAhkicsE3QAjkJYoRiYiUMwwAjnguRiCMq515_atsZZ6Cr4qpWzJZx700i_gYuucT7A5QZKC8dqo2qj4ItujXWmhMbCuWxNVAf4Zdp3ONNr2Tql67qrpYcT6VUkG3kMDipZB32yqyPwdjNdTGbJw_Pt3WT8kCgm8jbhskQEE04yhKSWeaYyxsi2jxPKRKqXiFe0rGSmUJpxKpZSScIlFwRVIqcjcNH7rr376HRoi8aE7TrSateFggtOWcpxBM9_gSvXeRt3Kwihgoqc0AjRHlLeheB1Vaz7sxQYFdsPFH98IKrOdtbdstHlD01_8ghc9kDThMLqVfOv3Tc154xc</recordid><startdate>19990401</startdate><enddate>19990401</enddate><creator>Saito, Akiko</creator><creator>Muto, Yasutoshi</creator><creator>Moriwaki, Hisataka</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19990401</creationdate><title>Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma</title><author>Saito, Akiko ; Muto, Yasutoshi ; Moriwaki, Hisataka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-6ad021262700aea87c744200ae2703495eb06f3dfa7c057639baca26a6920f983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Neoplasms, Second Primary - prevention & control</topic><topic>Survival Analysis</topic><topic>Tretinoin - analogs & derivatives</topic><topic>Tretinoin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Akiko</creatorcontrib><creatorcontrib>Muto, Yasutoshi</creatorcontrib><creatorcontrib>Moriwaki, Hisataka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Akiko</au><au>Muto, Yasutoshi</au><au>Moriwaki, Hisataka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1999-04-01</date><risdate>1999</risdate><volume>340</volume><issue>13</issue><spage>1046</spage><epage>1047</epage><pages>1046-1047</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor:
Chemoprevention can prevent second primary cancers in patients with cancer,
1
but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the
Journal
that oral administration of an acyclic retinoid for 12 months significantly reduced the incidence of second primary cancers in patients who had received curative treatment for hepatocellular carcinomas,
2
but the effect on survival did not reach statistical significance after a median follow-up period of 38 months.
We have subsequently reexamined the patients every three months. Patients in whom a second primary hepatocellular carcinoma developed received mainly . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>10189289</pmid><doi>10.1056/NEJM199904013401315</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1999-04, Vol.340 (13), p.1046-1047 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69634561 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Follow-Up Studies Humans Liver Neoplasms - drug therapy Liver Neoplasms - mortality Neoplasms, Second Primary - prevention & control Survival Analysis Tretinoin - analogs & derivatives Tretinoin - therapeutic use |
| title | Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20Second%20Primary%20Tumors%20by%20an%20Acyclic%20Retinoid%20in%20Patients%20with%20Hepatocellular%20Carcinoma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Saito,%20Akiko&rft.date=1999-04-01&rft.volume=340&rft.issue=13&rft.spage=1046&rft.epage=1047&rft.pages=1046-1047&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199904013401315&rft_dat=%3Cproquest_cross%3E69634561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223939823&rft_id=info:pmid/10189289&rfr_iscdi=true |